The Recent Growth of Biotech Clusters Around the Globe

David Brindley, Senior Research Fellow at University of Oxford Department of Pediatrics comes from a very interesting background that covers both academia and industry. He joined us during Biotech Week Boston to discuss the relationship between academia and industry, what he identifies as the key regulatory challenges in both the US & Europe, and then finally he explores the recent growth of biotech clusters around the globe.

By design, there are a number of initiatives around that globe to create biotech clusters. “The two greatest biotech clusters in the world are undoubtedly the 128 corridor around Boston and Silicon Valley on the West Coast” Brindley says. However, he does mention that these clusters were development completely by accident, and not by design. Moving forward, as the growing of biotech cluster initiatives progress, these regional hubs need to focus/specialize on a very deep niche. If you are looking to set up a new cluster, Brindley says, “you should worry less about the platform technology it will develop,  is it monoclonal or is it small molecule. And [instead], focus more on ‘what is the bioprocessing problem that we are going to address here? Is this going to be a center of manufacturing?’ because I think even saying we are going to be a center of drug development is too broad.” This train of thought shows that collaboration is necessary for large-scale success of the industry.

Continue reading “The Recent Growth of Biotech Clusters Around the Globe”

“There is a lot we need to develop yet to get a robust manufacturing process” – interview with Dr. Julie Allickson

Dr. Julie Allickson is the Director of Translational Research at Wake Forest Institute for Regenerative Medicine.

We spoke to her about the future of regenerative medicine and the importance of learning the academic model for translation of regenerative medicine, as well as regulatory issues and differences within the industry by geography.

Continue reading ““There is a lot we need to develop yet to get a robust manufacturing process” – interview with Dr. Julie Allickson”

“Five years ago if you’d said to any big pharma company: “You’re going to be working in patient specific autologous medicines”, I think they would have laughed at you” – Dr Mark Lowdell, UCL, RFH

As Director of Cellular Therapy & Biobanking at Royal Free London NHS Foundation Trust, Dr Mark Lowdell is at the cutting edge of cellular therapies, genetically modified cell therapies and 3D tissue engineering therapies. With the industry changing at such a rapid rate, many researchers’ focus is changing year on year, and for Dr Lowdell it is no different.

Continue reading ““Five years ago if you’d said to any big pharma company: “You’re going to be working in patient specific autologous medicines”, I think they would have laughed at you” – Dr Mark Lowdell, UCL, RFH”